The CSL Ltd (ASX: CSL) share price is in focus after the company posted total revenue of US$15.8 billion, down 1%, and underlying NPATA of US$3.1 billion, also down 2%. A statutory net loss after tax of US$2.6 billion reflected significant one-off costs and impairments for the year ended 30 June 2026.
Image source: Getty Images
What did CSL Ltd report?
- Total revenue: US$15.8 billion, down 1% on the prior year
- Underlying NPATA: US$3.1 billion, down 2%
- Reported NPAT (Loss): US$2.6 billion, down 184%
- Final dividend: US$1.62 per share, unchanged
- Cash flow from operations: US$3.5 billion, steady
- Share buyback program: A$1 billion completed
What else do investors need to know?
CSL described FY26 as a "reset year", with the company undertaking a broad transformation program. This included cost savings of around US$176 million, integration of Behring and Vifor operations, and restructuring costs of US$799 million.
Pre-tax asset impairments totalled US$7.1 billion, largely due to changes in commercial outlook, generic competition, regulatory updates, and site utilisation assumptions. CSL also entered a strategic partnership with VarmX for a novel blood coagulation treatment and announced plans to expand its US plasma manufacturing network.
What did CSL Ltd management say?
Gordon Naylor, Interim Chief Executive Officer and Managing Director, said
FY26 has been a year of reset. We have taken decisive action and created a clear path to return to sustainable growth.
Plasma market fundamentals and demand remain robust and momentum is building behind our newer therapies, such as ANDEMBRY® and HEMGENIX.
We have made solid progress on our transformation program and continue to simplify the business. We have also invested in our commercial capabilities and development programs to drive top line growth in the future.
What's next for CSL Ltd?
CSL expects revenue in FY27 to be steady, with underlying NPAT forecast to grow by approximately 5%. CSL Behring anticipates mid-single digit revenue growth, particularly in immunoglobulin, while CSL Seqirus expects low single digit growth amid softer immunisation rates in the US. The Vifor segment is forecast to decline due to generic competition and regulatory changes.
Management remains positive on returning to growth, supported by a strong balance sheet, additional US$1.1 billion share buyback program, and continued investment in new therapies and manufacturing.
CSL share price snapshot
It is no secret that the CSL share price has been among the worst performers on the S&P/ASX 200 index (ASX: XJO) over the past 12 months. During this time, its shares have lost 50% of their value.
